Janus Kinase inhibitors (JAKi) – MIMS – New risk minimisation measures
01/01/2023
Medicines for human use
Safety update
This article was produced by the HPRA for publication in the January/February edition of Monthly Index of Medical Specialties (MIMS) and describes new recommendations to mitigate risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality when JAKi are used in the treatment of chronic inflammatory disorders.